“The ability to differentiate between cancer and healthy tissue during radical prostatectomy is crucial to successful prostate cancer surgery. The ability of a device like the Dune Medical device would be a significant help to surgeons and patients.”
Results of a study published in the journal Nature.com demonstrate the utility of Dune Medical Devices’ MarginProbe® technology in prostate cancer surgery. The system uses RF spectroscopy to identify tissues’ electromagnetic signature, which differs in cancerous tissues to the extent that they can be identified at a minutely accurate level.
Founded in 2002 Dune Medical Devices possesses proprietary tissue characterisation technology which it believes has extraordinary medical potential. The company’s MarginProbe System is its first commercial product and is already available in Europe. Dune’s patented radiofrequency spectroscopy technology on which the device is based offers surgeons and radiologists the real time ability to identify cancerous tissues and react immediately. In procedures such as radical prostatectomy it is a tool to aid surgeons in complete removal of the prostate gland while achieving so-called negative surgical margins.
The Nature.com study reports results of over 15,000 measurements in 49 patients, which validates the company’s claim by showing accurate discrimination between cancer and healthy tissue.
“The ability to differentiate between cancer and healthy tissue during radical prostatectomy is crucial to successful prostate cancer surgery,” said Dr. Zohar Dotan, head of uro-oncology service at Sheba Medical Center in Tel Hashomer, Israel. “Positive margins after radical prostatectomy are common, and increase the probability of biochemical failure and salvage radiotherapy following surgery. Existing techniques to help the surgeon intraoperatively are inadequate. The ability of a device like the Dune Medical device would be a significant help to surgeons and patients.”
“The ability to detect prostate cancer margins with a high degree of accuracy represents significant opportunity to improve the standard of care in prostate cancer surgery,” said Dune’s President & Chief Technology Officer, Dr. Dan Hashimshony. “This represents another application of MarginProbe technology and just as our MarginProbe System represents a powerful tool in surgeons’ fight against breast cancer, we believe these data show similar opportunity in prostate cancer surgery. We believe that the technology platform upon which both products were developed represents substantial opportunity for multiple surgical oncology applications.”
The MarginProbe device is an investigational device that is not yet available for sale in the U.S.
Source: Dune Medical Devices, PR Newswire